The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Targeted Therapies End the Dry Spell in AML Drug Development

Christin L. Melton
Published Online: Feb 06,2019

Mark J. Levis, MD, PHD

Courtney Dinardo, MD, MSCE

Targeted agents are routinely used to treat many cancers and have improved outcomes for patients with solid tumors and hematological malignancies alike. Recently, targeted therapies made their way into the armamentarium for acute myeloid leukemia (AML), representing the first therapeutic advances for AML in decades.1 Since 2017, the FDA has approved at least 6 molecularly targeted drugs for AML, including inhibitors of FMS-like tyrosine kinase 3 (FLT3), isocitrate dehydrogenase (IDH) 1, IDH2, B-cell lymphoma 2 (BCL2), and the Hedgehog pathway. The advances are especially pertinent for elderly patients, who account for most new diagnoses, are more likely to have cytogenetic aberrations, and have worse outcomes than their younger counterparts.2 Elderly patients are often unfit for standard intensive chemotherapy or hematopoietic stem cell transplant.3,4

Ongoing clinical trials are evaluating other investigational agents and combination regimens, making it likely the armamentarium for AML will continue to expand. In addition to agents that target IDH or FLT3, investigators are assessing drugs with novel targets, such as BET, LSD1, NPM1, DOT1L, BRDR4, or MDM2.1 Antibody–drug conjugates that target CD33 and other isotopes are in development.
 

FLT3 Inhibitors


FLT3 inhibitors are classified as first- or second-generation based on their selectivity for FLT3, a receptor tyrosine kinase that promotes proliferation and survival of hematopoietic cells.5

“FLT3 is the gene most commonly mutated in AML; FLT3 mutations occur in more than one-quarter of all patients,” said Mark J. Levis, MD, PhD, director of the Adult Leukemia Service and professor of oncology, medicine, and pharmacology at Johns Hopkins University School of Medicine in Baltimore, Maryland. An FLT3 mutation predicts more aggressive disease.1,6 Approximately 75% of FLT3 mutations are internal tandem duplication (ITD) mutations,7 and the rest are point mutations in the tyrosine kinase domain (TKD).8 FLT3 inhibitors are further categorized as type I (pan-FLT3 inhibitors) when active against FLT3-ITD and FLT3-TKD mutations or as type II when active primarily against FLT3-ITD mutations.5 Treatment with type II FLT3 inhibitors can lead to the emergence of FLT3-TKD–resistant clones and faster relapse.1

Midostaurin (Rydapt) was the first FLT3 inhibitor approved by the FDA and is indicated in combination with standard induction and consolidation chemotherapy for FLT3-positive adults with newly diagnosed AML.9 Approval was based on findings from the phase III randomized placebo-controlled RATIFY trial, which included 717 patients aged 18 to 61 years with an activating FLT3 mutation.7 Compared with placebo, midostaurin significantly prolonged overall survival (OS; HR, 0.78; 1-sided P = .009) and event-free survival (EFS; HR, 0.78; 1-sided P = .002) with similar efficacy in patients with FLT3-ITD or FLT3-TKD mutations.7

Gilteritinib (Xospata) is a highly selective FLT3 inhibitor approved as monotherapy for relapsed or refractory AML in FLT3-positive adults.6 Gilteritinib also inhibits AXL, a receptor tyrosine kinase frequently upregulated in AML that drives resistance to FLT3 inhibition.6 Levis is an investigator for the phase III ADMIRAL trial that led to FDA approval in November 2018, which he described as “the culmination of years of effort to develop an FLT3 inhibitor.” The FDA also approved a companion assay to screen patients for FLT3 mutations. “Patients should be tested at diagnosis and at every major clinical change, such as relapse or disease progression,” said Levis.

The ADMIRAL trial compared gilteritinib 120 mg daily with salvage chemotherapy in adults with relapsed or refractory AML and an FLT3 mutation.10 An unpublished interim analysis showed 21% (29/138) of patients in the gilteritinib arm had achieved complete remission (CR) or CR with partial hematologic recovery at median follow-up of 4.6 months.10 Detailed safety data were not reported, but in the phase I/II CHRYSALIS trial, a dose-escalation study of gilteritinib salvage therapy, the most common treatment-related adverse events (TRAEs) were diarrhea, fatigue, and elevated liver enzymes.6

Levis said gilteritinib is more potent and better tolerated than midostaurin or sorafenib (Nexavar), a multikinase inhibitor studied in AML.6 “Gilteritinib can induce responses as a single agent, which is never the case for midostaurin and is much less likely with sorafenib,” Levis said. Several clinical trials “incorporating this drug into all phases of therapy—from frontline to posttransplant maintenance” are underway and that a head-to-head comparison of gilteritinib versus midostaurin in newly diagnosed AML will soon begin recruiting, he said.

In the phase III QuANTUM-R trial, 367 adults with relapsed/ refractory FLT3-ITD–positive AML were randomized 2:1 to quizartinib monotherapy or chemotherapy.11 Quizartinib prolonged OS significantly more than chemotherapy (6.2 vs 4.7 months, respectively; HR, 0.76; 95% CI, 0.58-0.98; 1-sided P = .0177) but did not significantly improve EFS.11 The CR composite rate was 48% in the quizartinib arm versus 27% in the chemotherapy arm (P = .0001). The most common grade ≥3 TRAEs in both arms were infections and cytopenia. An approval decision from the FDA regarding quizartinib is anticipated in May 2019.12

Crenolanib was evaluated with intensive chemotherapy in a phase II trial that included 44 adults with newly diagnosed AML and activating FLT3 mutations.13 Analyses of data for 27 participants aged ≤60 years found that 81% were alive at median follow-up of 24 months. Investigators are now recruiting FLT3-positive patients aged 18 to 60 with newly diagnosed AML for a phase III randomized trial comparing crenolanib with midostaurin after induction and consolidation therapy.13
 

IDH Inhibitors


IDH1 and IDH2 are primarily somatic mutations that occur in about 20% of patients with AML.14 The FDA recently approved ivosidenib (Tibsovo) and enasidenib (Idhifa). Ivosidenib is indicated for patients with relapsed or refractory AML with an IDH1 mutation and enasidenib is indicated for patients with relapsed or refractory IDH2-mutated AML.

Courtney DiNardo, MD, MSCE, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, helped develop ivosidenib. “About 8% of patients with AML have an IDH1 mutation. They are enriched in the older patient population, so the older you are, the more likely an IDH1 mutation is present,” said DiNardo. Approval was based on data for 174 adult patients with relapsed/refractory IDH1-positive AML who received ivosidenib 500 mg daily in a single-arm during a phase I dose-escalation trial.15 The rate of CR plus CR with partial hematologic recovery was 32.8% (95% CI, 25.8%-40.3%). “About 20% of patients who respond to ivosidenib actually clear the IDH1 mutation,” DiNardo said, adding that this may predict more durable responses, although more data are needed.

The most frequent serious TRAEs in the study were leukocytosis, QT prolongation, and differentiation syndrome, a potentially fatal event.16 Labels for both ivosidenib and enasidenib include a black box warning concerning differentiation syndrome,16, 17 which according to a FDA study occurs in approximately 20% of patients.18 Symptoms include dyspnea, unexplained fever, weight gain, hypotension, acute kidney injury, and pulmonary infiltrates/ pleuropericardial effusion. Differentiation syndrome can arise days or months after starting treatment and requires prompt corticosteroid treatment.16,17

Enasidenib was evaluated in a phase I/II trial featuring 109 adults with relapsed/refractory AML and an IDH2 mutation.19 The overall response rate was 40%, median response duration was 5.8 months, and median OS was 9.3 months. Approximately 19% of patients attained CR.19
Ivosidenib and enasidenib are each being evaluated in combination with standard induction and consolidation therapy for newly diagnosed AML.14 Both are also being investigated in combination with azacitidine in patients with newly diagnosed AML who are ineligible for intensive chemotherapy. Several other IDH inhibitors are being studied in clinical trials, including AG-881, which is active against IDH1 and IDH2.14
 

Treatment of AML in Patients Unsuited for Intensive Chemotherapy


Individuals 65 years and older account for almost 60% of new cases2 and generally have a poor prognosis.20 Comorbidities often prevent elderly patients from receiving intensive chemotherapy. Other biological factors may preclude patients of any age from receiving intensive chemotherapy, including unfavorable cytogenetic profile, prior systemic therapy, or a history of myelodysplastic syndrome or myeloproliferative neoplasm.20

In 2018, the FDA approved 2 targeted agents for patients with newly diagnosed AML who are 75 years or older or otherwise ineligible for intensive chemotherapy: venetoclax (Venclexta), a BCL2 inhibitor; and glasdegib (Daurismo), a Hedgehog pathway inhibitor.21, 22 Although both are molecularly targeted agents, their use is not restricted to individuals with cytogenetic abnormalities. Venetoclax is administered with a hypomethylating agent (HMA) such as azacitidine, decitabine, or low-dose cytarabine (LDAC); and glasdegib is given with LDAC.21,22

Accelerated approval of venetoclax was based on findings from 2 open-label clinical trials involving patients with newly diagnosed AML. Study M14-358 included 145 patients 65 years and older who were ineligible for intensive chemotherapy. Overall, 67% of patients achieved CR or CR with incomplete count recovery, maintained for a median of 11.3 months.23 Median OS was 17.5 months overall and not reached in the cohort treated with 400-mg venetoclax plus an HMA. Study M14-387 included 61 patients 60 years and older who received venetoclax plus LDAC.24 DiNardo said the combination of venetoclax with an HMA was “well tolerated and effective” and she expects it will become standard care for patients who cannot tolerate intensive chemotherapy. She said a phase III study of venetoclax plus azacitidine is underway, as are other combination studies.

Glasdegib received FDA approval based on results from the phase II BRIGHT 1003 trial, which randomly assigned adults with newly diagnosed AML 2:1 to glasdegib plus LDAC (n = 77) or LDAC only (n = 38).25 The CR rate in the combination arm was 18.2% compared with 2.6% in the LDAC-only arm. The addition of glasdegib to LDAC was associated with a 54% reduction in the risk of death.25
 

Conclusions


Drug discovery for AML is encouraging, with several new drugs approved and others under investigation in clinical trial results. “These therapies are already improving the outcomes of patients in the clinic,” DiNardo said. “Future rational combinations with these novel agents will serve to even further improve upon AML therapy,” she said.

“The addition of targeted therapies—in combination with the ability to do a bone marrow transplant more safely—is increasing the overall cure rate for most patients,” Levis said. The next focus “is to use targeted agents only, phasing out intensive chemotherapy,” he added.

The National Comprehensive Cancer Network has updated its guidelines for AML26 to help physicians determine when it is appropriate to incorporate the newly approved therapies. Physicians should also consult the prescribing information for additional information about the risks, benefits, and precautions required when treating patients with one of the new AML drugs.
 
 
References:
  1. Perl AE. The role of targeted therapy in the management of patients with AML. Hematology Am Soc Hematol Educ Program. 2017;1(24):54-65. doi: 10.1182/asheducation-2017.1.54.
  2. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: leukemia - acute myeloid leukemia (AML). https://seer.cancer.gov/statfacts/html/amyl.html. Accessed December 31, 2018.
  3. Silva P, Neumann M, Schroeder MP, et al. Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape. Leukemia. 04/03/online 2017;31:1640. doi: 10.1038/leu.2017.109.
  4. Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep. 2016;6:1-7. doi: 10.1016/j.lrr.2016.06.001.
  5. Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther. 2017;16(6):991-1001. doi: 10.1158/1535-7163.MCT-16-0876.
  6. Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3.
  7. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454-464. doi: 10.1056/NEJMoa1614359.
  8. DiNardo CD, Stone RM, Medeiros BC. Novel therapeutics in acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2017;37:495-503. doi: 10.14694/EDBK_175401.
  9. Rydapt [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018. https://astellas.us/docs/xospata.pdf. Updated November 2018. Accessed January 18, 2019.
  10. US Food and Drug Administration [press release]. FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm627045.htm. Published December 17, 2018. Accessed January 8, 2019.
  11. Cortes JE, Khaled SK, Martinelli G. Efficacy and safety of single-agent quizartinib (Q), a potent and selective FLT3 inhibitor (FLT3i) in patients (pts) with FLT3-internal tandem duplication (FLT3-ITD)-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML) enrolled in the global, phase 3, randomized controlled Quantum-R trial. Blood. 2018;132(suppl 1):Abstract 563.
  12. Broderick J. Quizartinib update presented as FDA weighs AML approval. https://www.onclive.com/conference-coverage/ash-2018/quizartinib-update-presented-as-fda-weighs-aml-approval. Published December 3, 2018. Accessed January 4, 2019.
  13. Walter RB, Collins RH, Stone RM. Addition of crenolanib to standard induction and consolidation therapies improved long-term outcomes in newly diagnosed FLT3-mutant AML patients <60 years old. Paper presented at: 23rd Congress of European Hematology Association, June 14-17, 2018; Stockholm, Sweden.
  14. Ragon BK, DiNardo CD. Targeting IDH1 and IDH2 mutations in acute myeloid leukemia. Curr Hematol Malig Rep. 2017;12(6):537-546. doi: 10.1007/s11899-017-0418-6.
  15. US Food and Drug Administration [press release]. FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm614128.htm. Published July 20, 2018. Accessed January 1, 2019.
  16. Tibsovo [package insert]. Cambridge, MA: Agios Pharmaceuticals, Inc.; 2018. https://www.tibsovopro.com/pdf/prescribinginformation.pdf. Updated July 2018. Accessed January 18, 2019.
  17. Idhifa [package insert]. Summit, NJ: Celgene Corporation; 2017. https://media.celgene.com/content/uploads/idhifa-pi.pdf. Updated July 2017. Accessed January 18, 2019.
  18. Norsworthy KJ, Mulkey MS, Ward AF. Incidence of differentiation syndrome with ivosidenib (IVO) and enasidenib (ENA) for treatment of patients with relapsed or refractory (R/R) isocitrate dehydrogenase (IDH)1- or IDH2-mutated acute myeloid leukemia (AML): a systematic analysis by the US Food and Drug Administration (FDA). Blood. 2018;132(suppl 1):Abstract 288.
  19. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722-731. doi: 10.1182/blood-2017-04-779405.
  20. Sacks NC, Cyr PL, Louie AC, et al. Burden of acute myeloid leukemia among older, newly diagnosed patients: retrospective analysis of data from the 2010-2012 Medicare limited data set. Clin Ther. 2018;40(5):692-703.e692. doi: 10.1016/j.clinthera.2018.03.012.
  21. Daurismo [package insert]. New York, NY: Pfizer Labs; 2018. http://labeling.pfizer.com/ShowLabeling.aspx?id=11336. Updated November 2018. Accessed January 18, 2019.
  22. Venclexta [package insert]. Chicago, IL: AbbVie Inc.; 2018. https://www.rxabbvie.com/pdf/venclexta.pdf. Updated November 2018. Accessed January 18, 2019.
  23. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17. doi: 10.1182/blood-2018-08-868752.
  24. US Food and Drug Administration [press release]. FDA approves venetoclax in combination for AML in adults. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626499.htm. Published November 21, 2018. Accessed January 2, 2019.
  25. Broderick J. FDA approves glasdegib for frontline AML. https://www.onclive.com/web-exclusives/fda-approves-glasdegib-for-frontline-aml. Published November 21, 2018. Accessed January 4, 2019.
  26. Network NCC. NCCN Guidelines for Acute Myeloid Leukemia, v. 3.2018. https://www.nccn.org/professionals/physician_gls/default.aspx. Updated November 30, 2018. Accessed January 5, 2019.



Clinical Articles

Targeted Therapies End the Dry Spell in AML Drug Development
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.